Clinical Trial Search

Primary: Number of Participants With Viral Suppression: HIV-1 RNA < 50 Copies/mL During the Induction Phase — 20; 8 Participants

Primary: Geometric Mean Titer 21 Days After the Study Vaccination — 58.60; 58.45; 377.94; 337.23 Titers

Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder-Rating Scale (ADHD-RS-IV) Parent Version: Investigator Administered and Scored - Total Score at Week 10…

Primary: Percentage of Participants With Ongoing Pregnancy at Week 8 — 45.2; 45.2; 42.9; 48.7 percentage of participants

Primary: Aqueous PGE2 Inhibition — 288.7; 320.4; 224.8 pg/ml

Primary: Anterior Chamber Inflammation (Flare) — 24.48; 21.93 photon count per msec (pc/ms)

Primary: Peak Aqueous Penetration — 688.87; 67.64; 447.1 ng/ml

Primary: Prevalence of Bronchiolitis Obliterans Syndrome (BOS) — 5; 19 participants

Primary: Percentage of Fully Compliant Participants — 0 percentage of participants

Primary: Skin Dryness Score — 0.15; 0.46; 0.14; 0.29 Units on a scale

Primary: Mean Score on Cosmetic Outcome Visual Analog Scale (VAS) — 45.4; 67.2 score on scale

Primary: Participants Experiencing Collisions During "Surprise Events" in Driving Simulator — 8; 17 participants

Primary: Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values — -25.8; -15.1; 0.8 Percent change — p=<0.0001

Primary: Number of Participants With Fibroid Devascularization Measured by Contrast Enhanced Magnetic Resonance Imaging (MRI) — 29; 29 participants

Primary: Composite of Major Adverse Events (MAE) Defined as Center-reported and Clinical Events Committee (CEC) Adjudicated Death, Stroke, and Myocardial Infarction (MI) — 47…